Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.

Learn the essential facts about fungal sinus infections, from recognizing early warning signs to understanding treatment ...

Bucks County specialty pharmaceutical company Optinose first started exploring mergers and licensing deals in early 2022.

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

In this randomized controlled trial, among patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, tezepelumab more effectively reduced nasal polyp size and sinonasal symptoms ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and 2023, according to a poster presented here. “That seems to have held the test ...

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis.

A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic rhinosinusitis.